DSY Dassault Systemes SA

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey 

Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care

New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration with Sanofi in clinical research. As part of this extension Sanofi will use the , building on the organizations’ vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally.

The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi’s pharmaceutical knowledge can help advance studies, amplifying the development of therapies with greater precision and impact.

Sanofi will employ Medidata’s expertise and capabilities in as part of the extension of this agreement. Medidata will provide consulting and end-to-end operational support.

“Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," said Lisa Moneymaker, chief strategy officer, Medidata. "Through this agreement, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the clinical development process.”

To learn more about the Medidata Experiences, please visit .

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at . Listen to our latest podcast, , and follow us at @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: .

Contact:

Medidata PR

Analyst Relations

Attachment



EN
28/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dassault Systemes SA

 PRESS RELEASE

Dassault Systèmes: Filing of the 2025 Universal Registration Document

Dassault Systèmes: Filing of the 2025 Universal Registration Document Press ReleaseVELIZY-VILLACOUBLAY, France — March 31, 2026 Filing of the 2025 Universal Registration Document (Euronext Paris: FR0014003TT8, DSY.PA) announces the filing on March 31, 2026 of its 2025 Universal Registration Document (constituting the Annual Financial Report) with the Autorité des marchés financiers.   This document is available on Dassault Systèmes’ website at (sections Regulated information or Events & Publications/ Reports). Hard copies of the 2025 Universal Registration Document are also available u...

 PRESS RELEASE

Dassault Systèmes : dépôt du Document d'enregistrement universel 2025

Dassault Systèmes : dépôt du Document d'enregistrement universel 2025 Communiqué de PresseVELIZY-VILLACOUBLAY, France — le 31 mars 2026 Dépôt du Document d’enregistrement universel 2025 (Euronext Paris : FR0014003TT8, DSY.PA) annonce que son Document d’enregistrement universel 2025 (valant rapport financier annuel) a été déposé auprès de l’Autorité des marchés financiers le 31 mars 2026. Ce document est disponible sur le site de la société à l’adresse (rubriques Information réglementée ou Evènements et publications/Rapports). Des exemplaires du Document d’enregistrement universel 2025 ...

 PRESS RELEASE

Dassault Systèmes: Amount of the dividend

Dassault Systèmes: Amount of the dividend Press ReleaseVELIZY-VILLACOUBLAY, France — March 24, 2026 Dividend (Euronext Paris: FR0014003TT8, DSY.PA) announces that the Board of Directors has decided to propose to the next General Meeting of Shareholders, to be held on May 20, 2026, a dividend of twenty-seven euro cents (€0.27) per share for the year 2025, payable in cash only. Shares would be traded ex-dividend as of May 27, 2026.Dividends would be made payable on May 29, 2026. Pascal Daloz, Chief Executive Officer & Chairman, comments: “A new phase of industrial transformation is unde...

 PRESS RELEASE

Dassault Systèmes : montant du dividende

Dassault Systèmes : montant du dividende Communiqué de PresseVELIZY-VILLACOUBLAY, France — 24 mars 2026 Dividende (Euronext Paris : FR0014003TT8, DSY.PA) annonce que son Conseil d’administration a décidé de proposer aux actionnaires, lors de l’Assemblée générale du 20 mai 2026, un dividende de vingt-sept centimes d’euros (0,27 €) par action au titre de l’exercice 2025, exclusivement en numéraire. La date de détachement du dividende serait fixée au 27 mai 2026. Le dividende serait mis en paiement le 29 mai 2026. Pascal Daloz, Président-Directeur Général de Dassault Systèmes, commente : ...

 PRESS RELEASE

Dassault Systèmes : déclaration du nombre d'actions et de droits de vo...

Dassault Systèmes : déclaration du nombre d'actions et de droits de vote au 28 février 2026 Communiqué de PresseVELIZY-VILLACOUBLAY, France — le 6 mars 2026 Déclaration du nombre d’actions et de droits de voteau 28 février 2026         (Euronext Paris : FR0014003TT8, DSY.PA) annonce ci-après le nombre total d’actions composant son capital et le nombre total de ses droits de vote au 28 février 2026, conformément aux articles 223-16 et 221-3 du Règlement Général de l’Autorité des marchés financiers. Nombre d'actions en circulation : 1 341 855 657 Nombre de droits de vote* : 2 013 481 153...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch